Skip to content

Released Nov 9, 2023, before the open

10-Q filed Nov 9, 2023, 40 days after period end · 0001764013-23-000133

Q2 2024 · 10-Q
Revenue—
Net Income-$58.66MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.45N/M vs Q2 2023N/M vs Q1 2024
Operating Cash Flowderived-$60,060,000N/M
Free Cash Flowderived-$60,094,000N/M

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2018
Net Income-$58.66M-$47.93M-$37.70M-$6.35M
EPS Diluted-$0.45-$0.41-$0.35—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR